Pharmaceutical Executive
Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Emily O’Conno
Advertisement
Articles by Emily O’Conno
Advertisement
Latest Updated Articles
- Challenges to the Specialty Business Model
June 17th 2014
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5